---
figid: PMC3523565__dddt-6-391f1
figtitle: Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
  signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes in
  melanoma
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC3523565
filename: dddt-6-391f1.jpg
figlink: /pmc/articles/PMC3523565/figure/f1-dddt-6-391/
number: F1
caption: 'Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
  signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes in
  melanoma. Downstream effectors of the pathway lead to increased survival and proliferation
  by various mechanisms (eg, increased transcription of genes and regulation of apoptotic
  proteins). Potential mechanisms of acquired resistance to BRAF inhibitor therapy
  are highlighted in red. BRAF inhibition can lead to activation of the MAPK pathway
  via acquisition of secondary NRAS Q61K mutations; RAF isoform signal switching (ARAF
  > BRAF > CRAF); truncation of BRAF, resulting in a form that is resistant to the
  inhibitor; amplification of BRAF; MEK1 C121S mutation; and increased expression
  of COT, a partner kinase.Abbreviations: PDGFRB, platelet-derived growth factor receptor
  beta; IGF-1R, insulin-like growth factor 1 receptor.'
papertitle: Dabrafenib and its potential for the treatment of metastatic melanoma.
reftext: Alexander M Menzies, et al. Drug Des Devel Ther. 2012;6:391-405.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9279165
figid_alias: PMC3523565__F1
figtype: Figure
redirect_from: /figures/PMC3523565__F1
ndex: c6bf7d2e-debb-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3523565__dddt-6-391f1.html
  '@type': Dataset
  description: 'Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
    signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes
    in melanoma. Downstream effectors of the pathway lead to increased survival and
    proliferation by various mechanisms (eg, increased transcription of genes and
    regulation of apoptotic proteins). Potential mechanisms of acquired resistance
    to BRAF inhibitor therapy are highlighted in red. BRAF inhibition can lead to
    activation of the MAPK pathway via acquisition of secondary NRAS Q61K mutations;
    RAF isoform signal switching (ARAF > BRAF > CRAF); truncation of BRAF, resulting
    in a form that is resistant to the inhibitor; amplification of BRAF; MEK1 C121S
    mutation; and increased expression of COT, a partner kinase.Abbreviations: PDGFRB,
    platelet-derived growth factor receptor beta; IGF-1R, insulin-like growth factor
    1 receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pdgfrb
  - Igf1r
  - Nras
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Pten
  - Raf1
  - Araf
  - Braf
  - Braf-rs1
  - Akt1
  - Map2k1
  - Map2k2
  - Mtor
  - Mapk3
  - Mapk1
  - PDGFRB
  - IGF1R
  - NRAS
  - KRAS
  - HRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - RAF1
  - ARAF
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - MAP2K1
  - MAP2K2
  - MTOR
  - MAPK3
  - MAPK1
  - kita
  - ngfra
  - pak2a
  - itpka
  - pdgfrb
  - nras
  - rab1ab
  - ptenb
  - raf1a
  - araf
  - braf
  - si:dkey-222f8.3
  - map2k1
  - map2k2a
  - mtor
  - mapk3
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
